Linkedin X-twitter
default home ad

Phase III BRUIN CLL-313: Pirtobrutinib Improves Progression-Free Survival Versus Bendamustine-Rituximab in Treatment-Naïve CLL/SLL

Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) treatment continues to shift away from chemoimmunotherapy toward targeted, continuous oral therapies. In the phase III BRUIN CLL-313 trial, the highly selective, non-covalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) demonstrated a marked progression-free survival advantage over bendamustine plus rituximab in treatment-naïve patients without TP53 aberrations, supporting a potential frontline option for this population.

Clinical Takeaway

Pirtobrutinib significantly reduced the risk of disease progression or death compared with bendamustine-rituximab in previously untreated CLL/SLL, with a substantially more favorable safety profile and fewer high-grade adverse events (AEs).

Drug Profile & Mechanism

  • Agent: pirtobrutinib (Jaypirca)
  • Class:
    • pirtobrutinib: non-covalent (reversible) BTK inhibitor
    • bendamustine: alkylating antineoplastic nitrogen mustard agent
    • rituximab: monoclonal anti-CD20 antibody
  • Mechanism of action:
    • pirtobrutinib: selectively inhibits BTK signaling independent of C481 mutation status, disrupting B cell receptor-mediated survival and proliferation
    • bendamustine: alkylates DNA causing cross-linking and strand breaks, resulting in cell-cycle arrest and apoptosis of malignant B cells
    • rituximab: binds CD20 on B lymphocytes, leading to B cell depletion via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis
  • Route of administration:
    • pirtobrutinib: oral
    • bendamustine & rituximab: intravenous (IV)
  • Dosing Schedule:
    • pirtobrutinib
      • 200 mg orally daily
    • bendamustine
      • 90 mg/m2 IV on days 1 and 2 of a 28-day cycle for 6 cycles
    • rituximab
      • 375 mg/m2 on day 1 of cycle 1 and 500 mg/m2 starting day 1 of cycles 2-6 of a 28-day cycle for a total of 6 cycles

Target Population

  • Adults with treatment-naïve CLL/SLL without del(17p) or TP53 mutation.

Phase 3 BRUIN CLL-313 Study Design (NCT05023980)

  • Study Type: Randomized, open-label, international, phase III trial
  • Population: Patients with treatment-naïve CLL/SLL without 17p deletion or TP53 mutation
  • Comparator: bendamustine plus rituximab
  • Treatment Regimen: Continuous pirtobrutinib monotherapy versus fixed-duration bendamustine-rituximab
  • Follow-Up Duration: Up to 5 years
  • Estimated study completion: August 2026

Endpoints

  • Primary Endpoint:
    • Progression-free survival (PFS)
  • Key Secondary Endpoints:
    • Overall survival (OS)
    • Overall response rate (ORR)
    • Duration of Response (DOR)

Efficacy Outcomes

  • Primary Endpoint Results:
    • Pirtobrutinib demonstrated a statistically significant and clinically meaningful improvement in PFS, reducing the risk of disease progression or death by approximately 80% compared with bendamustine-rituximab.
  • Secondary Endpoint Results:
    • ORR: Higher with pirtobrutinib versus chemoimmunotherapy
    • DOR: Responses were more durable with continuous pirtobrutinib therapy
  • Overall Survival:
    • OS (Final Analysis): Immature at the time of reporting
    • Median OS: Not reached in either arm
    • Hazard ratio for death: Immature at the time of reporting

Regulatory Milestones

  • Approval Status: Approved for relapsed or refractory CLL/SLL; frontline indication under investigation
  • Regulatory Pathway: Phase III registrational trial supporting a potential frontline label expansion
  • Regulatory Review: Not yet initiated for frontline CLL/SLL; dependent on mature efficacy and safety data

Safety

  • Overall AE Burden: Lower with pirtobrutinib compared to bendamustine-rituximab
  • Grade ≥3 Events:
    • pirtobrutinib: ~40%
    • bendamustine-rituximab: ~67%
  • Treatment-related deaths: Infrequent and comparable between treatment arms
  • Notable toxicity patterns:
    • Pirtobrutinib was associated with fewer cytopenias and less treatment-limiting toxicity than chemoimmunotherapy
    • Safety profile consistent with prior studies of non-covalent BTK inhibition

Key Clinical Implications

✔ Supports pirtobrutinib as a highly effective frontline option for CLL/SLL without TP53 aberrations

✔ Demonstrates substantial PFS benefit over traditional chemoimmunotherapy

✔ Offers a favorable tolerability profile with fewer high-grade toxicities

✔ Reinforces the shift away from bendamustine-based regimens in frontline CLL

✔ Highlights the clinical value of continuous oral BTK inhibition in early-line disease

Bottom Line

In the phase III BRUIN CLL-313 trial reported by Jurczak et al., pirtobrutinib significantly improved PFS with fewer high-grade AEs compared with bendamustine-rituximab, supporting non-covalent BTK inhibition as a compelling frontline option for patients with treatment-naïve CLL/SLL without TP53 aberrations.

Sources:

Share the Post:
default home ad
default home ad

Related Posts

Join Our Newsletter